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Abstract
Aims: Application of advanced molecular pathology in rare tumours is hindered by low 
sample numbers, access to specialised expertise/technologies and tissue/assay QC and 
rapid reporting requirements. We assessed the feasibility of co- ordinated real- time cen-
tralised pathology review (CPR), encompassing molecular diagnostics and contemporary 
genomics (RNA- seq/DNA methylation- array).
Methods: This nationwide trial in medulloblastoma (<80 UK diagnoses/year) introduced 
a national reference centre (NRC) and assessed its performance and reporting to World 
Health Organisation standards. Paired frozen/formalin- fixed, paraffin- embedded tumour 
material were co- submitted from 135 patients (16 referral centres).
Results: Complete CPR diagnostics were successful for 88% (120/135). Inadequate sam-
pling was the most common cause of failure; biomaterials were typically suitable for 
methylation- array (129/135, 94%), but frozen tissues commonly fell below RNA- seq QC 
requirements (53/135, 39%). Late reporting was most often due to delayed submission. 
CPR assigned or altered histological variant (vs local diagnosis) for 40/135 tumours (30%). 
Benchmarking/QC of specific biomarker assays impacted test results; fluorescent in- 
situ hybridisation most accurately identified high- risk MYC/MYCN amplification (20/135, 
15%), while combined methods (CTNNB1/chr6 status, methylation- array subgrouping) 
best defined favourable- risk WNT tumours (14/135; 10%). Engagement of a specialist 
pathologist panel was essential for consensus assessment of histological variants and im-
munohistochemistry. Overall, CPR altered clinical risk- status for 29% of patients.
Conclusion: National real- time CPR is feasible, delivering robust diagnostics to WHO 
criteria and assignment of clinical risk- status, significantly altering clinical management. 
Recommendations and experience from our study are applicable to advanced molecular 
diagnostics systems, both local and centralised, across rare tumour types, enabling their 
application in biomarker- driven routine diagnostics and clinical/research studies.
Neuropathol Appl Neurobiol. 2021;47:736–747.   |736 wileyonlinelibrary.com/journal/nan
INTRODUC TION
Advanced upfront molecular diagnostics and pathology review are 
an increasing requirement in contemporary cancer care and clinical 
trials. As next- generation technologies such as high- throughput se-
quencing and DNA methylation- array profiling unearth novel and 
clinically significant insights in the research setting, their adoption 
into routine diagnostics and/or standard clinical care is imperative.
Diagnostics delivery in rare tumour types (typically <5 patients per 
100,000 population per year1) presents specific and significant chal-
lenges. Care pathways for such diseases vary with clinical setting but 
are commonly characterised by systems involving low patient numbers 
spread across multiple treatment centres. In such settings, co- ordinated 
multicentre approaches offer opportunities to address issues including 
access to specialist analytical technologies and expertise, analysis of tu-
mour and associated biomaterials across multiple centres, tissue/assay 
quality control and standardisation, requirements for integrated diag-
noses encompassing molecular genetic analysis and histopathological 
review and prompt reporting to accredited standards. For many tumour 
types, these processes must be completed prior to the commencement 
of adjuvant therapy, typically within an approximately 30- day window 
following primary surgical resection or biopsy.
Centralised diagnostics pathways offer significant potential to 
address these issues. However, the implementation and perfor-
mance of centralised molecular pathology review (CPR) systems 
for rare tumours, and their clinical impact, have not been widely or 
systematically assessed. Such trials will be essential to support the 
clinical adoption of such schema and to generate experience which 
can be applied more widely in routine diagnostics.
Medulloblastoma is an important example of a rare tumour 
type where molecular advances are rapidly informing its diagnos-
tic requirements and treatment. Medulloblastoma is a clinically and 
molecularly heterogeneous embryonal tumour arising in the cerebel-
lum, which accounts for ~10% of all childhood cancer deaths. Until 
recently, medulloblastoma was classified solely by its clinically rele-
vant histological variants, based on morphologic and immunocyto-
chemical criteria; desmoplastic/nodular (DN), medulloblastoma with 
extensive nodularity (MBEN), classic (CLA), large cell and anaplastic 
(LCA).2 In 2012, international consensus was reached on the defini-
tion of four primary medulloblastoma molecular subgroups— WNT 
and SHH (each named by the predominant mutated molecular path-
way that drives their development), Group3 and Group4. Each group 
is defined by distinct genome- wide gene expression and DNA meth-
ylation patterns and harbours distinct subtypes with characteristic 
clinical and biological features.3– 5 Moreover, a series of diagnostic 
and prognostic biomarkers, with established clinical relevance, have 
now been identified and validated, showing consistent clinical be-
haviour across multiple studies. These include nuclear accumulation 
of β- catenin and activating mutations in its coding gene, CTNNB1, 
and monosomy of chromosome 6— as biomarkers of favourable- risk 
WNT subgroup disease.6 Validated high- risk biomarkers include 
MYC or MYCN amplification, LCA pathology and TP53 mutation (in 
SHH tumours).3,7,8
Importantly, medulloblastoma molecular biomarkers (molecular 
subgroups, TP53 status) were incorporated, alongside histological 
variants, into the World Health Organisation (WHO) 2016 classifi-
cation of central nervous system (CNS) tumours.2 Moreover, these 
are now being used alongside clinical indices to deliver risk- adapted 
and targeted treatment strategies in first molecularly driven medul-
loblastoma clinical trials (NCT02066220, NCT01878617), aimed at 
improving outcomes and reducing late- effects. Early studies of the 
targeted inhibition of the SHH pathway9 are in progress. The intro-
duction and rapid upfront assessment of contemporary biomarkers 
is, thus, essential for entry of medulloblastoma patients into inter-
national biomarker- driven trials, and their adoption as ‘standard of 
care’. Finally, exemplifying requirements in many rare tumour types, 
the assessment, cross- validation and definition of optimal methodol-
ogies for detection of specific biomarkers (e.g. MYC/N amplification, 
WNT subgroup status), including the relative performance of con-
ventional and next- generation technologies, is a critical requirement 
in their standardisation and clinical adoption.
We assessed whether the introduction of national real- time CPR 
for medulloblastoma in the United Kingdom would lead to the effec-
tive and robust delivery of essential contemporary diagnostics and 
consequent improved clinical stratification. The annual incidence 
of medulloblastoma in the United Kingdom is ~80; patients are di-
agnosed and treated across over 16 specialised treatment centres 
associated with the UK Children's Cancer and Leukaemia Group 
(CCLG; https://www.cclg.org.uk/). In the United Kingdom, virtually 
all CNS tumour diagnosis is undertaken by specialist neuropatholo-
gists (with evidence of specialist training in brain tumour diagnosis 
and on- going expertise demonstrated by external quality assur-
ance), according to ISO15189 standards within the UKAS (United 
Kingdom Accreditation Service) framework; this national network, 
thus, offers a unique opportunity to assess the experience of CPR 
implementation in practice.
We, therefore, undertook a national multicentre feasibility study 
of real- time medulloblastoma CPR, to establish a routine diagnostics 
infrastructure on behalf of all UK CCLG centres and to assess the 
experience and impact of CPR, incorporating next- generation tech-
nologies for biomarker assessment. We systematically assessed CPR 
in 135 patients, demonstrating that it is feasible, provides robust 
network (co- funded by The Brain Tumour 
Charity, Great Ormond Street Children's 
Charity, and Children with Cancer UK). 
TSJ is supported by the National Institute 
for Health Research and a Great Ormond 
Street Hospital UCL Biomedical Research 
Centre award.
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diagnostics to WHO standards and significantly alters clinical man-
agement in the setting of initial local diagnosis followed by referral 
to a national reference centre (NRC). Based on our findings and ex-
perience, we proffer recommendations generalisable to all rare tu-
mours, and different diagnostic systems. These should help enable 
optimisation of pathology review and molecular diagnostics, recruit-
ment to clinical trials and delivery of high- quality surplus tumour 
material suitable for comprehensive molecular research studies in 
these diseases.
MATERIAL S AND METHODS
Study design
This link- anonymised national trial was set up to investigate the 
feasibility of real- time medulloblastoma diagnostics within a clini-
cally defined timeframe (i.e. before the start of adjuvant ther-
apy) (Figure 1A). Diagnostic assessments (fluorescent in- situ 
hybridisation [iFISH] for MYC/MYCN amplification status, β- catenin 
immunohistochemistry [IHC]), undertaken in laboratories accred-
ited under UKAS to International Standards (ISO 15189:2012), along 
with central pathology review, were performed in real time with the 
intention of reporting results within a 30- day period. Research as-
sessments (mutational analysis for CTNNB1 and TP53, molecular 
subgroup analysis by 450k methylation- array and RNAseq and copy 
number calling by multiplex ligation- dependent probe amplification 
(MLPA) and methylation- array) were performed post hoc on DNA 
and RNA derived from frozen study samples to evaluate sample han-
dling and DNA/RNA quality.
Patient recruitment, registration, sample 
shipping and reporting
The study was open to all UK patients from 2009 to 2015. 16 UK 
CCLG treatment centres submitted eligible patients defined as: any 
patient with a local diagnosis of MB for whom both formalin- fixed, 
paraffin- embedded (FFPE) and frozen tissue tumour material were 
available (n = 135, median age at diagnosis, 7.59 years). Submitting 
F I G U R E  1  A UK national trial of 
centralised real- time medulloblastoma 
molecular diagnostics: Study workflow, 
specimen handling and turnaround 
times. (A) Study overview. Molecular 
subgroups are shown in their consensus 
colours WNT, blue; SHH, red; Group3, 
yellow; Group4, green. Boxplots showing 
turnaround times (days) for (B) iFISH 
tissue processing and preparation and (C) 
iFISH analysis and reporting. Boxplots 
showing turnaround times (days) for 
(D) histopathology tissue preparation/
IHC and (E) central pathology review 
and reporting. (F) Overall turnaround 
time from receipt in the NRC to issue 
of final report to local centre. Dotted 
lines represent mean turnaround time 
+1 SD. Cases that exceeded the overall 
turnaround threshold of mean +1 SD (F) 
were coloured according to the reason 
for delay; technical IHC repeats (black), 
additional CPR (blue) and NRC personnel 
availability (green). Proportion of cases 
assigned to category are shown in (G). 
Abbreviations: FZN, Frozen tissue; FFPE, 
formalin- fixed paraffin- embedded; QC, 
quality control; MLPA, multiplex ligation- 
dependent probe amplification
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centres were required to register patients and send tumour material 
to an NRC at the Newcastle on Tyne NHS Hospitals Trust/Newcastle 
University, according to standard operating procedures (SOPs; 
Supporting Information online). An approved courier was used for 
overnight transport of human tumour samples from the local centre 
to the NRC on dry ice (frozen tissue) or at ambient temperature (FFPE 
tissue). Time taken for shipment, tissue processing and reporting 
of centralised diagnostic assessments (i.e. central pathology review 
and molecular testing) was recorded. Diagnostic results were not re-
ported back to submitting centres under the terms of study ethics ap-
proval; however, technical metrics (success or failure) were reported.
Diagnostic assessments
Formalin- fixed, paraffin- embedded histology
For immunohistochemistry [IHC], histology tissue sections of 4 μm 
were cut on a rotary microtome and mounted onto Superfrost plus 
slides (Thermo Scientific, 1014356190) and dried at 60°C for 1 
hour. H&E was carried out to standard protocols and reticulin was 
stained according to the Gordon and Sweet method10 (Supporting 
Information online). A medulloblastoma diagnostic IHC panel was 
applied to premounted slides with their appropriate control sec-
tions using the fully automated Ventana BenchMark XT IHC system 
(Supporting Information online).
Central pathology review
Stained slides from each patient were assigned to one of four pathol-
ogists from the UK Children's Cancer and Leukaemia Group (T.S.J., 
K.R., S.B.W. and A.J.), and centrally reviewed according to WHO 
2007 criteria.11 Tumours were classified into the following histo-
logical variants; CLA (9470/3), LCA (9474/3), DN (9471/3) or MBEN 
(9471/3). Local pathologists could elect not to define variant in an-
ticipation of assignment by CPR. For cases where the CPR variant 
call was discrepant to the local call, each remaining pathologist was 
requested to additionally review, before consensus on histopatho-
logical variant classification was reached between pathologists. 
Tumour cell content was assessed in all cases.
β- catenin immunohistochemistry scoring
All 16 samples that were either mutant for CTNNB1 or positive for 
β- catenin IHC nuclear localisation (≥10% of cells) on initial analysis 
were sent for blinded, independent, review to three neuropatholo-
gists (S.B.W., T.S.J., K.R.), alongside 16 samples that were CTNNB1 
wild- type or showed β- catenin IHC nuclear localisation in <10% of 
cells. All samples were rescored; consensus was defined based on 
agreement of ≥2 neuropathologists.
Nucleic acid extraction
DNA was isolated from fresh frozen and FFPE primary tumour biopsy 
material according to established methods (Supporting Information 
online).
Fluorescence in- situ hybridisation
Frozen tissue was assessed for tumour content by H&E staining of 
8 μm frozen sections; touch imprints were prepared from the ex-
posed face and then interphase FISH for MYC/LAF and MYCN/IGH 
was carried out using standard protocols (Supporting Information 
online). MYC(N) amplification scoring was as per Ryan et al.12 and 
the SIOP- PNET5- MB protocol; scoring was undertaken by two in-
dependent assessors, as previously described. 13,14
RESEARCH QUALITY ASSESSMENTS
Mutational analysis
TP53 (exons 4– 9) and CTNNB1 (exon 3) mutation status was as-
sessed by direct polymerase chain reaction (PCR)– based DNA se-
quence analysis according to the protocols described in Hill et al.15 
and Ellison et al.16
Molecular subgroup assessment
Intact DNA of >500 ng, in a total volume of <45 μl, was suitable 
for methylation- array (Illumina). RNA quantity and quality was 
assessed by Agilent 2100 Bioanalyser and those RNAs >800 ng 
and with an RNA integrity number (RIN) >5 were suitable for 
RNAseq and subsequent molecular subgrouping. Subgrouping 
according to methylation and expression profiles was achieved 
using established methods.3 SHH and Group3/Group4 second- 
generation subtypes were assigned according to the ‘Grp3 and 
Grp4 Classifier’ found at https://www.molec ularn europ athol ogy.
org/mnp/class ifier/ 7.5
Copy number estimation
As well as iFISH (see above), copy- number for MYC(N) was estimated 
by 1) MLPA and 2) (additionally for chromosome 6) 450 k array probe 
intensity values using the R package conumee,17 as previously de-
scribed.18 Copy- number assessment by MLPA (using SALSA rea-
gents; MRC- Holland) for MYC(N) were as described15 and measured 
relative to four independent reference loci (B2 M, TBP, 7q31 and 
14q22).
For further detail, see Supporting Information online.
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RESULTS
Turnaround times
A total of 135 samples were received by the NRC from 16 treat-
ment/referral centres. The mean and median interval between date 
of surgery and arrival at the NRC was 24 and 14 days, respectively. 
The range of 1– 301 days reflected the study protocol; specifically, 
guidance was issued that allowed samples to be registered and sub-
mitted without specific time limits, to maximise cohort size and as-
sessment of NRC performance.
A total of 127/135 (94%) samples were processed for iFISH 
within 8 days of receipt by the NRC (a calculated threshold, defined 
as the mean processing time plus 1 standard deviation (SD); dashed 
line Figure 1B). iFISH analysis and reporting was completed within 
11 days of dispatch from the NRC (mean + 1 SD) for 130/135 (96%; 
Figure 1C). A total of 121/135 (90%) of tissues were processed for 
histology/IHC within 9 days (mean + 1 SD; Figure 1D), and subse-
quent central pathology review was completed within 15 days for 
94% (127/135). Overall, results for 120/135 (88%) of cases were re-
ported to the submitting local centre within 23 days of receipt by the 
NRC (Figure 1F). For those for which the mean + 1 SD time thresh-
old was exceeded (15/135; 12%), reasons included personnel un-
availability (53%; 8/15), additional CPR (second opinion, additional 
requested histology and/or IHC; 5/15 [33%]) and technical IHC re-
peats required within the NRC (2/15; 14%; Figure 1G). The mean 
and median intervals between date of surgery and final reporting 
was larger, at 40 and 28 days, respectively (range 14– 332 days), re-
flecting the permissive recruitment approach with regard to patient 
registration and sample submission to the NRC.
Sufficiency of biological material to support 
contemporary diagnostics and next- 
generation analyses
We examined whether current tissue handling practices across 
UK treatment centres were sufficient to provide the abundant 
F I G U R E  2  Next- generation molecular 
diagnostics: quality control and suitability 
of extracted nucleic acids for molecular 
subgrouping. Bar plots of DNA (A) and 
RNA (B) extraction yields from tumour 
material. Light purple, no remaining tissue 
postnucleic acid extraction; dark purple, 
remaining tissue. Red lines represent 
typical quantity thresholds that must 
be exceeded to allow for downstream 
research assessments including molecular 
subgrouping. (C) RIN assessment of RNA 
quality. Red line represents a quality 
threshold of 5, below which samples 
are ineligible for RNAseq. Non- negative 
matrix factorisation (NMF) clustering 
of (D) DNA methylation profiles and (E) 
expression profiles. Pie charts summarise 
molecular subgroup assignments derived 
from (F) DNA methylation- array or (G) 
RNAseq. Failed samples are shown in 
shades of grey; reasons for failure are 
poor nucleic yield, low quality RNA 
(RIN < 5) and insufficient tissue. H, 
Molecular subgroup assignment by DNA 
methylation- array (consensus 4- subgroup 
assignment and second- generation 
subtype) and RNAseq (consensus 
4- subgroup assignment)
[Correction added on 31 May 2021, 
after first online publication: Panel (C) 
was mislabelled previously and has been 
added in this version.]
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high- quality tumour material typically required for contemporary 
diagnostics and research methodologies. The majority (102/135; 
76%) of frozen tissue samples yielded more than 5000 ng of dsDNA; 
73% of those had surplus tissue remaining for further extraction. 
Furthermore, 124/135 (92%) exceeded a threshold of 2000 ng 
dsDNA (red line Figure 2A), which allowed for all real- time diagnos-
tic and post hoc research methodologies to be carried out (Sanger 
sequencing, methylation- array and MLPA). Conversely, RNA was 
extracted from 126/135 (93%) of frozen tissues with failures due to 
sample limitations. 116/125 of attempted RNA extractions yielded 
more than a threshold amount of 800 ng (Figure 2B, red line), nec-
essary for RNAseq. RNA quality was assessed by the RIN; 73% 
(91/125) of those measured had RIN>5, indicating the RNA was of 
sufficient quality for RNAseq (Figure 2C).
Molecular subgrouping
Overall, 133/135 (99%) samples yielded DNA of sufficient quality 
and quantity for methylation- array; 81/135 (60%) were suitable 
for RNAseq. Non- negative matrix factorization (NMF) was used 
to cluster cohort methylation3 (Figure 2D) and expression profiles 
(Figure 2E). Four subgroup- specific metagenes were defined; a sup-
port vector machine (SVM) classifier assigned subgroups (WNT, SHH, 
Group3 and Group4). Samples classified with <80% confidence (by 
resampling procedures) were deemed to be non- classifiable (NC).5
Robust consensus subgroup assignment (>80% confidence) was 
achieved for 129/132 (98%) DNA methylation profiles; Group3/
Group4 second- generation subtypes recently defined by Sharma 
et al. within Group3 and Group45 were confidently assigned for 
128/132 (97%) and showed the expected distribution (subtype VIII 
predominated in Group4; II, III and IV were the majority subtypes 
in Group3; Figure 2H). Success rates were comparable for RNAseq- 
based subgroup assignment (75/81, (93%); Figure 2F,G), demonstrat-
ing that when DNA and RNA entry criteria thresholds for sample 
requirements are consistently applied (e.g. concentration, RIN), sam-
ples rarely fail to exceed 80% confidence estimates for subgroup 
assignment.
CPR is critical for robust diagnosis of 
histological variants
Following diagnosis at their local treatment centre, all samples were 
reviewed centrally by a panel of three experienced neuropatholo-
gists, according to the 2007 WHO classification of tumours of the 
CNS (Figure 3A).11 Tumours that could not be classified histologically 
according to this scheme were termed medulloblastoma, not other-
wise specified (MB- NOS).
All submitted tumours were diagnosed locally as medulloblas-
toma; 105/135 (78%) had a pathology variant assigned locally. CPR 
changed (10/105, 10%) or assigned (30/135, 20%) pathology vari-
ant for 40/135 (30%) of tumours. Reticulin staining was crucial in 
resolving misclassifications, indeed, reclassification of DN tumours 
as CLA was the predominant recurrent reclassification (n = 5), with 
other reclassifications occurring infrequently (Figure 3C). Overall, 
variant frequencies following CPR were CLA (69%; 93/135), LCA 
(15%, 20/135), DN (11%, 15/35) and MBEN (0%, 0/135). Five percent 
(7/135) remained without a definitive histological variant post- CPR, 
F I G U R E  3  Central pathology review (CPR): concordance with 
local pathology assessment. A, Representative micrographs to 
show the WHO (2007) histological variants assessed in this study; 
large cell/anaplastic, CLA, DN and MBNOS. No tumours were 
classified as MBEN by CPR. Magnifications of ×20 are shown. 
Scale bar = 200 μm. B, Stacked bar plot showing proportion of 
pathological variants assigned by local review vs CPR. Key shows 
colours used to denote pathological variants. C, Pie chart to show 
the nature of revised pathology calls between local (subscript 
text) and CPR. Abbreviations: HE, haematoxylin and eosin (gross 
morphology); Retic, reticulin (marker of desmoplasia); Ki- 67 (marker 
of proliferation); CLA, classic; DN, desmoplastic/nodular; MBEN, 
medulloblastoma with extensive nodularity; LCA, large cell/
anaplastic; MBNOS, medulloblastoma not otherwise specified
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either due to insufficiency of supplied tumour material (n = 2) or dif-
ficult to interpret complex histologies (n = 5). Tumour cell content 
was assessed on a section of frozen biopsy material as part of CPR 
and exceeded 60% in all cases (mean, 87%; range 60%– 100%).
Multi- assay WNT assessment improves 
subgroup assignment
WNT subgroup status was used as an exemplar to assess inter- 
observer variability in IHC interpretation. WNT subgroup medul-
loblastomas are defined by activation of the Wnt/Wg signalling 
pathway, associated with nuclear accumulation of the β- catenin 
protein, CTNNB1 mutation and monosomy of chromosome 6.6,16 β- 
catenin IHC methods have historically been used to evaluate WNT 
subgroup status, but inter- observer variability and sample het-
erogeneity may confound this assessment.19 All cases showing any 
evidence of β- catenin nuclear accumulation in real- time CPR (1%– 
100%; n = 14), selected negative controls (n=10) and all CTNNB1mut 
cases (n = 8) were subjected to a further round of independent, 
blind, pathology review by all three neuropathologists (total n = 32; 
Figure 4A,B). IHC consensus was defined as agreement between 
two or more pathologists and concurred with initial CPR in 25/32 
(78%) of cases.
We then tested how diagnostic accuracy compared with mo-
lecular evaluation; methylation- array- based subgrouping, Chr6 
monosomy and RNAseq- based subgrouping. The defining WNT 
consensus call was determined by either CTNNB1mut or positivity for 
two or more of the four WNT status measures. Methylation- array 
and RNAseq subgroup calls had 100% sensitivity and specificity; 
Chr6 monosomy had a specificity of 100% and 88% sensitivity. Of 
the IHC evaluations, consensus 3- pathologist review status was 
more sensitive than initial CPR (82% vs 64%), with indistinguishable 
specificities (89%). Two cases were false positives by primary CPR 
IHC, compared with the WNT consensus call, and were negative for 
all other WNT measures.
MYC and MYCN amplification assessment: fluorescent 
in- situ hybridisation is a clinical diagnostic ‘gold 
standard’
iFISH was attempted in all samples received (Figure 5A, representa-
tive analyses). Out of the 117 (87%) successful MYC and MYCN iFISH 
assays, 6% were MYC amplified (n = 8), and in 9% MYCN was ampli-
fied (n = 12). Technical failures affected 13% (n = 18) of the cohort 
(MYC, n = 6, 4%; MYCN, n = 3, 2% or both n = 9, 7%; Figure 5B). 
Due to this failure rate and the increasingly common adoption of 
F I G U R E  4  Biomarker assay assessment and validation I: WNT molecular subgroup— comparison of IHC and molecular methods and 
blinded assessment of interpathologist concordance. A, Illustrative immunohistochemistry (IHC) micrographs showing variation in nuclear 
β- catenin accumulation in WNT subgroup cases (>20% and 1%– 20%). A non- WNT subgroup case (0% nuclear β- catenin accumulation, 
membranous staining only) is also shown. Magnifications of ×20 are shown, scale bar = 200 μm. B, A comparative analysis of WNT subgroup 
assignment methods. Primary assessment of WNT status by 1) % nuclear β- catenin accumulation determined by CPR (white text in black 
boxes shows % nuclear accumulation >10%, those cases with evidence of nuclear positivity <10% shown in black text) and 2) CTNNB1 
mutation status (amino acid changes given). % nuclear β- catenin accumulation >10% is also shown for a blinded, three- pathologist IHC 
evaluation exercise with consensus between 2 or more pathologists from CPR and the blinded evaluation exercise shown by black shading. 
Assessment of WNT status by molecular analyses are shown. Cases with monosomy 6 are identified by black shading, DNA methylation- 
array (consensus 4- subgroup, and second- generation subtype) and RNAseq subgroup calls are shown. An overarching WNT consensus 
call (defined by either CTNNB1 mutation status or IHC positivity plus at least one other molecular method) is shown, and each WNT status 
assignment methods is compared to this consensus (Sens., sensitivity; Spec., specificity). Grey boxes, negative results; white, not done
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alternative methods for MYC and MYCN amplification status assess-
ment, we undertook CN analysis using DNA methylation- array17 
(successful in 133/135) and MLPA20 (successful in 124/135, MYC; 
126/135, MYCN; Figure 5C; illustrative examples). Of the nine cases 
shown to be MYC amplified by iFISH, seven also had elevated copy 
number by MLPA along with 11 false- positive cases. A total of 88 
cases showed no evidence of MYC amplification, in agreement with 
iFISH data (not shown) (overall MLPA sensitivity, 78%; specificity, 
88%). DNA methylation- array analysis showed complete specificity 
but poor sensitivity (62%; Figure 5D). These observations were re-
capitulated for MYCN amplification analysis, with 9 of the 12 iFISH 
positive cases also showed elevated copy number by MLPA, but with 
a number of false positives (n = 10; sensitivity, 75%; specificity, 92%; 
Figure 5E). DNA methylation- array analysis showed the same sen-
sitivity (75%) but had a no false positives (specificity, 100%). MYC- 
and MYCN- amplified cases showed the expected subgroup- specific 
distributions; the vast majority (8/9) of MYC- amplified cases were 
Group3 (Figure 5D), whereas 11/12 MYCN amplified cases were 
SHH (n = 6) or Group4 (n = 5; Figure 5D,E).
Application and impact of CPR: diagnosis to SIOP- 
PNET5- MB and WHO (2016) criteria
The pan- European SIOP- PNET5- MB clinical trial of standard- risk me-
dulloblastoma (NCT02066220) stratifies medulloblastoma patients 
from 3– 22 years of age at diagnosis upfront using clinical and bio-
logical criteria, tested in real time. We applied the SIOP- PNET5- MB 
clinical trial entry criteria to our cohort, to forecast likely recruit-
ment to a risk- stratified clinical trial (Figure 6A). A total of 115/135 
met the age criteria of 3– 22 years. Of these 115 patients, 27 (23%) 
would have been ineligible for entry into the trial. For 14/115 (12%) 
F I G U R E  5  Biomarker assay assessment 
and validation II: MYC and MYCN 
amplification— comparison of iFISH, 
DNA methylation- array copy number 
profiling and MLPA methods. A, iFISH 
micrographs representing amplified (A I, II) 
and nonamplified (A III, IV) tumours. Red; 
MYC or MYCN, green LAF4 (for MYCN) or 
IGH (for MYC) controls. Bb, Frequency 
of MYC and MYCN amplification, and 
technical failures, across the trial 
cohort. C, example MYC and MYCN 
amplified tumours determined using by 
DNA methylation- array (upper panel) 
or MLPA (lower panel). A comparative 
evaluation of iFISH MYC (D) and MYCN 
(E) status assignment vs MLPA and DNA 
methylation- array. Black boxes represent 
amplification of MYC/MYCN; grey boxes, 
negative for amplification; white boxes, 
NA. Numbers in iFISH track are % of 
amplified nuclei. DNA methylation- array 
(consensus 4- subgroup and second- 
generation subtype) subgroup calls are 
shown. MLPA and DNA methylation- 
array MYC and MYCN assignment calls 
are compared to iFISH (Sens., sensitivity; 
Spec., specificity)
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of these ineligible patients, this was due to potentially avoidable 
assay failures. Furthermore, 13/115 patients (11%) would have been 
excluded due a failure to complete pathology review or molecular 
diagnostics within the interval mandated by SIOP- PNET5- MB (we 
applied a maximum of 10 days for receipt by the NRC, then a cut- off 
of a further 28 days for final reporting by the NRC).
In total, there were 88 patients with the complete clinical and 
biological data required to assess trial entry criteria. Of those 88, 
13 showed evidence of high- risk biological and pathological fea-
tures (MYC(N) amplification and/or LCA pathology), which would 
have rendered them ineligible for the SIOP- PNET5- MB. Thirty- six 
further patients would have been excluded based on the pres-
ence of high- risk clinical features (incomplete surgical resection, 
n = 11; metastatic disease, n = 25), leaving 34% of age- appropriate 
patients (39/115) eligible for SIOP- PNET5- MB. A total of 26% 
(10/39) of these were WNT- positive, compatible with eligibility for 
the favourable- risk trial arm, with the remaining 74% (29/39) con-
sidered standard- risk.
The 2016 World Health Organization (WHO) classification of 
tumours of the CNS recognises five distinct medulloblastoma mo-
lecular variants; (1) WNT- activated, (2) SHH- activated TP53 mutant, 
(3) SHH- activated TP53 wild- type, (4) non- SHH/non- WNT (encom-
passing Group3 and Group4 as provisional variants).2 In our cohort, 
non- SHH/non- WNT predominated as expected; 36% (n = 49) were 
Group4 and 24% (n = 33) were Group3. Fourteen (10%) WNT pa-
tients were identified (Figure 6B). TP53 mutation status subdivided 
the SHH group into the respective TP53 mutant (n = 7, 5%) and wild- 
type (n = 26, 19%) groups. Overall, 96% of our cohort were success-
fully classified to WHO (2016) standards; this was not possible for 
the remainder due to a lack of molecular subgroup data.
Taken together, 29% (33/115) of patients had altered risk- status 
based on CPR and molecular assessments made (i.e. assignment of 
MYC(N), LCA, WNT and SHH- TP53 status).
DISCUSSION
This study has established and implemented centralised real- time 
medulloblastoma molecular pathology for the United Kingdom. In 
this setting within the UK clinical system (i.e. 16 dispersed local 
treatment centres), CPR at an>a NRC enhanced the diagnostic pro-
cess through improved histological variant assignment, molecular 
variant assignment, assessment of risk- biomarker status including 
application of next- generation technologies and consequent assign-
ment of disease risk- status.
Care and referral systems differ globally, defined by factors in-
cluding population density, geography and national care systems for 
specific diseases (e.g. dispersed networks of local treatment centres 
vs large referral/treatment centres), alongside associated availabil-
ity of molecular diagnostic technologies. From our experience, we 
provide recommendations for routine pathology review and molec-
ular diagnostics, which are applicable in different care systems and 
can inform the design and delivery of current and future diagnostic 
testing and clinical trials (Table 1). These findings apply not only in 
medulloblastoma but also for other rare tumours, where collection 
and rapid assessment of biological material is key.
Histopathologic and associated review practice also varies signifi-
cantly internationally. The UK neuropathology community provides 
a key framework to enable assessment of the value and impact of 
CPR within a highly specialised group of professionals. In the United 
Kingdom, neuropathologists qualify to practice following specialist 
training (assessed by examination) and participate in regular ongoing 
mandatory national EQA activities (https://www.bns.org.uk/eqa- 
schem e/). Therefore, all tumours, prior to CPR, have been diagnosed 
by a specialist. We observed that, where local neuropathologists had 
assigned a medulloblastoma histological variant, there was a good 
degree of concordance with CPR calls, although significant discor-
dances did occur (10/105; 10%); the distinction between certain DN 
variants and CLA tumours represented the most common discrep-
ancy. Furthermore, in many cases, local neuropathologists did not 
assign a histological variant and CPR did; this may in part reflect local 
practice to use CPR for variant calling. Overall, variant was assigned 
or altered by CPR in 30% (40/135) of patients, strongly supporting 
the added value of the CPR process. In any central review system, 
it is essential to have mechanisms in place to identify and examine 
discrepancies between local and central opinion, and to reach con-
sensus, and the involvement of multiple reference pathologists in 
the CPR team was critical to this. We further anticipate discordance 
F I G U R E  6  Application and impact of 
CPR and molecular diagnostics: diagnosis 
to SIOP- PNET5- MB and WHO (2016) 
criteria. A, Application of SIOP- PNET5- 
MB clinical trial criteria and (B) the 2016 
World Health Organization classification 
of CNS tumours2 to our cohort. 
Abbreviations: LCA, large cell/anaplastic; 
R+, incompletely resected disease; M+, 
metastatic disease
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will be greater in circumstances where brain tumours are assessed 
by nonspecialist pathologists and/or more dispersed models of prac-
tice; based on our experience, we recommend review by multiple 
expert pathologists as essential in such instances. The introduction 
of tools to support the diagnosis of histologically defined variants 
(e.g. image analysis, associated biomarkers) represents a promising 
area for future development.
Considering sampling and logistical aspects; trained, profes-
sionally accredited staff, working to clear and concise SOPs are 
essential at all stages. These include practice in the surgical the-
atre, where resource limitations and cultural practices can cause 
conflicting priorities between resection of the tumour, diagnos-
tics and the ability to sample adequate biomaterials. Later, the 
processing of samples and the coordination of their pathology 
review, molecular diagnostics and reporting can also impact. 
Importantly, we observed a lack of prompt patient registration 
and shipment of biomaterials to the NRC. Of note, the study pro-
tocol did not permit intervention; guidelines were issued, and 
patient registration/sample submission was allowed to proceed 
without influence by the NRC. Marked improvements are antici-
pated in settings where real- time molecular diagnostics are man-
dated clinically to defined timescales. Indeed, this has been borne 
out by the improved submission rates and turnaround times on 
the SIOP- PNET5- MB medulloblastoma trial (NCT02066220), 
now underway; we estimate that >90% of UK medulloblastomas 
were submitted to the NRC in 2019. We anticipate the obligation 
to meet such eligibility criteria will be a strong driver of timely 
completion of the CPR pathway.
Once samples reached the NRC, outcomes were more consis-
tent. The vast majority (88%) had completed diagnostic assessment 
within 23 days of receipt at the NRC; delays were typically due to 
personnel availability, the requirement for repeat analyses and fur-
ther CPR. Insufficiency of submitted biomaterials was apparent, and 
we concur with previous recommendations21 that a minimum of 
1.5 cm3 of FFPE tissue and 0.5 cm3 of frozen tumour tissue should 
be collected where possible. However, in this study we found that 
the quality of frozen tumour material was a greater risk to successful 
delivery of molecular diagnostics. Although DNA is less sensitive to 
poor tissue- handling practices (reflected by the near- total ability to 
perform successful DNA methylation array), frozen material submit-
ted was often not suitable for RNA- seq- based analysis. Although it 
is true that RNAseq sets a high bar for quality, and other molecular 
tests are suitable for use on RNA of lesser quality and/or quantity 
(e.g. RT- PCR, nanoString, ISH), or on DNA extracted from FFPE sam-
ples (e.g. DNA methylation array and NGS methods), it is neverthe-
less vitally important that the practice and culture of the operating 
room and pathology laboratory acknowledges the critical require-
ment for sufficient biomaterial sampling and rapid handling. Portions 
of samples should be immediately snap frozen and stored appropri-
ately at – 80°C, to ensure their preservation for contemporary in-
vestigations, and to support research programmes. Furthermore, 
routine molecular diagnostics should be based on methods that are 
not sensitive to nucleic acid degradation, where possible. Finally, 
factors such as the nature of essential biomarkers, availability of 
cross- disease methodologies (e.g. WGS) and cost/benefit consider-
ations will also strongly influence the requirements for sample col-
lection procedures, referral pathways and required biomaterials, for 
specific diseases.
TA B L E  1  Recommendations for the delivery of advanced 
molecular pathology for rare tumours in real- time, including 
medulloblastoma- specific recommendations
Scope Recommendations
All rare tumours Overarching governance
Adequate number of well- trained staff
Clear and concise SOPs
Patient registration
Prompt consenting and registration
Sampling and sample handling
Sufficient FFPE and promptly snap- frozen 
tumour tissue (10 mm3)
Prompt transfer from surgical theatre to 
pathology lab
Prompt shipping to reference centre/central 
site/biobank
Sample movement logistics (centralised 
systems)
Establishment of appropriate material transfer 
agreements
Excellent lines of communication between local 
and reference centres
Use of reliable courier
Real- time molecular diagnostics and pathology 
review
Undertake sample quality assurance
Initiate all molecular testing in parallel to 
ensure timely completion
Use robust, validated tests, performed in 
accredited laboratories
Pathology review with a multineuropathologist 
review panel
Prompt reporting pathways
Provision of biomaterials for research 
investigations
Adequate biobanking systems and facilities
Anonymised coupling of tumour material data 
to comprehensive patient data
Medulloblastoma WNT subgroup assessment
CTNNB1 mutation and DNA methylation- based 
classification are robust, sensitive and specific
Consider monosomy 6 or RNA- based 
classification, as supportive assessments
MYC(N) amplification assessment
iFISH is the diagnostic ‘gold standard’
Abbreviations: CPR, central pathology review; FFPE, formalin- fixed, 
paraffin- embedded; SOPs, standard operating procedures.
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Prompt liaison between local centres and NRCs is essential to 
ensure the timely and secure transit of biomaterials, with an infra-
structure governance provided by the use of appropriate material 
transfer agreements. Once received by the NRC, robust tests per-
formed in accredited laboratories, which first assess material qual-
ity and suitability for assessment, must be applied.22 Although not 
collected in our study, workflows for the adequate collection and 
storage of other biomaterials such as blood (for the assessment of 
tumour predisposition syndromes and germline genetic variation), 
CSF (for liquid biopsy approaches) and additional frozen tumour ma-
terial for proteomics should be built into practice.
The introduction of MB molecular biomarkers into the CPR pro-
cess both (i) enabled determination of associated risk- status and (ii) 
highlighted requirements for the assessment and validation of any 
specific biomarker prior to its diagnostic use. Although specific bio-
markers for any given disease will change over time – for instance, 
GAB1 and YAP1 IHC are now commonly used alongside β- catenin 
to refine IHC- based subgrouping of medulloblastoma16,19— common 
underpinning principles may be established from our data.
For instance, in our study, assignment to the WNT biologi-
cal subgroup was most reliable using multiple independent mea-
sures. CTNNB1 mutation was both sensitive to most tumours and 
specific; however, a small proportion of CTNNB1 wild- type WNT 
cases alternatively harbour APC mutations.23 Molecular subgroup-
ing by DNA methylation- array was robust, sensitive and specific; 
methylation- based methods are now entering the diagnostic rep-
ertoire but are not available in all institutions and require assess-
ment at specialist centres.24 Therefore, independent assays and/or 
supporting measures are needed for the diagnostic assessment of 
molecular subgroup and, as such, this forms the current recommen-
dation of the International Society for Paediatric Oncology (SIOP).22 
Interpretation of β- catenin IHC was highly variable in our blinded 
assessment of concordance between pathologists, supporting the 
requirement for objective molecular methods in this instance. The 
gold standard molecular analysis of MYC and MYCN status is iFISH, 
but failures were observed in our study. Improved success rates may 
have been observed if FFPE material had been used for iFISH, but 
nevertheless our experience suggests a requirement for collection 
of high- quality frozen tissues and a role for additional methodolo-
gies. DNA methylation- array approaches were highly specific but 
were prone to false negatives,25 possibly reflecting tumour hetero-
geneity, whereas MLPA methods commonly yielded false positives 
and were unsuitable for primary detection of gene amplifications.
Benchmarking and validation vs the current gold standard is, 
thus, required in the development/adoption of any new biomarker 
method. For example, array comparative genomic hybridization 
(aCGH) has been shown to be perform equivalently to iFISH for the 
detection of MYC/MYCN gene amplification.26 As novel (including 
NGS) technologies become available clinically for mutation, copy 
number and methylation assessment, robust validation against the 
current ‘gold standard’ becomes a key requirement.
Finally, reporting of molecular diagnostics to the local and/or 
treating centre must be in accordance with disease guidelines or the 
clinical study protocol. We (i) assessed diagnosis of our cohort to 
WHO (2016) standards and (ii) modelled enrolment from our cohort 
to the biomarker- driven SIOP- PNET5- MB clinical trial, by reviewing 
our cohort against the tissue, NRC performance, clinical and molec-
ular criteria required for trial recruitment. In our study, 23% (27/115) 
samples would have been ineligible due to delayed registration and 
turnaround times or low biomaterial quantity and quality; these fac-
tors can be managed and must be optimised to maximise popula-
tions eligible for recruitment to specific clinical studies. Of the 115 
patients with complete data, 33 (29%) had altered risk status as a 
consequence of CPR assessments (i.e. assignment of MYC/MYCN, 
LCA, WNT and SHH- TP53 status).
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